198 related articles for article (PubMed ID: 28258912)
1. Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma.
Moussa E; Zamzam M; Kamel A; Salah Z; Attia I; Gaber L; Soliman R; Ezzat S
J Egypt Natl Canc Inst; 2017 Mar; 29(1):53-56. PubMed ID: 28258912
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center.
Watts RG; George M; Johnson WH
Cancer; 2012 Apr; 118(7):1919-24. PubMed ID: 21882180
[TBL] [Abstract][Full Text] [Related]
4. Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients.
Kakadekar AP; Sandor GG; Fryer C; Chan KW; Rogers PC; Pritchard S; Popov R
Med Pediatr Oncol; 1997 Jan; 28(1):22-6. PubMed ID: 8950332
[TBL] [Abstract][Full Text] [Related]
5. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma.
Bini I; Asaftei SD; Riggi C; Tirtei E; Manicone R; Biasin E; Basso ME; Agnoletti G; Fagioli F
Cardiol Young; 2017 Nov; 27(9):1815-1822. PubMed ID: 28780919
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-related cardiotoxicity: are Australian practitioners missing the point?
Conyers R; Costello B; La Gerche A; Tripaydonis A; Burns C; Ludlow L; Lange P; Ekert P; Mechinaud F; Cheung M; Martin M; Elliot D
Intern Med J; 2017 Oct; 47(10):1166-1172. PubMed ID: 28485067
[TBL] [Abstract][Full Text] [Related]
8. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
9. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
11. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
[TBL] [Abstract][Full Text] [Related]
12. Utility of Echocardiography as Screening for Late-onset Anthracycline-induced Cardiotoxicity in Pediatric Cancer Survivors: Observations from the First Decade After End of Therapy.
Moke DJ; Schubert LE; Sun HY; Printz BF; Dietz AC
J Pediatr Hematol Oncol; 2018 Jul; 40(5):e283-e288. PubMed ID: 29432303
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive early detection of anthracycline-induced cardiotoxicity in patients with hematologic malignancies using the phased tracking method.
Saito Y; Susukida I; Uzuka Y; Kanai H
Cancer Med; 2016 Sep; 5(9):2276-85. PubMed ID: 27484957
[TBL] [Abstract][Full Text] [Related]
15. Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer.
Ruiz-Pinto S; Pita G; Patiño-García A; Alonso J; Pérez-Martínez A; Cartón AJ; Gutiérrez-Larraya F; Alonso MR; Barnes DR; Dennis J; Michailidou K; Gómez-Santos C; Thompson DJ; Easton DF; Benítez J; González-Neira A
Pharmacogenet Genomics; 2017 Dec; 27(12):445-453. PubMed ID: 28961156
[TBL] [Abstract][Full Text] [Related]
16. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
[TBL] [Abstract][Full Text] [Related]
18. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
[TBL] [Abstract][Full Text] [Related]
19. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
[TBL] [Abstract][Full Text] [Related]
20. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.
Armenian SH; Gelehrter SK; Vase T; Venkatramani R; Landier W; Wilson KD; Herrera C; Reichman L; Menteer JD; Mascarenhas L; Freyer DR; Venkataraman K; Bhatia S
Clin Cancer Res; 2014 Dec; 20(24):6314-23. PubMed ID: 24947931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
